Inhibition of plasmin activity by tranexamic acid does not influence inflammatory pathways during human endotoxemia

Arterioscler Thromb Vasc Biol. 2004 Mar;24(3):483-8. doi: 10.1161/01.ATV.0000118280.95422.48. Epub 2004 Jan 22.

Abstract

Objective: Plasmin activates several proinflammatory pathways at the cellular level in vitro. Lipopolysaccharide (LPS) administration to healthy humans results in a rapid generation of plasmin activity, accompanied by activation of a number of inflammatory systems.

Methods and results: To determine the role of early plasmin activity in LPS-induced inflammation in vivo, 16 healthy males received an intravenous bolus injection with LPS (from Escherichia coli, 4 ng/kg) directly preceded by a 30-minute intravenous infusion of tranexamic acid (2 g, n=8), a plasmin activation inhibitor, or placebo (n=8). LPS injection induced marked increases in the plasma levels of D-dimer and plasmin-alpha2-antiplasmin complexes, indicative of plasmin activation and generation, respectively, which were strongly attenuated by tranexamic acid (both P<0.01 versus placebo). However, tranexamic acid did not influence LPS-induced coagulation activation, granulocytosis, neutrophil activation (expression of CD11b, CD66b, and L-selectin) or degranulation (plasma concentrations of elastase-alpha1-antitrypsin and bactericidal permeability-increasing protein), endothelial cell activation (plasma levels of von Willebrand factor and soluble E-selectin), or cytokine release.

Conclusions: These data argue against a role of early plasmin generation in the subsequent activation of other inflammatory pathways during human endotoxemia.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antithrombin III / analysis
  • Binding, Competitive
  • Biomarkers
  • Cytokines / blood
  • Endotoxemia / blood*
  • Fibrin Fibrinogen Degradation Products / analysis
  • Fibrinolysin / biosynthesis*
  • Fibrinolysis / drug effects
  • Humans
  • Lipopolysaccharides / toxicity
  • Male
  • Peptide Fragments / analysis
  • Peptide Hydrolases / analysis
  • Plasminogen / metabolism*
  • Prothrombin / analysis
  • Tranexamic Acid / pharmacology*

Substances

  • Biomarkers
  • Cytokines
  • Fibrin Fibrinogen Degradation Products
  • Lipopolysaccharides
  • Peptide Fragments
  • antithrombin III-protease complex
  • fibrin fragment D
  • prothrombin fragment 1.2
  • Tranexamic Acid
  • Antithrombin III
  • Prothrombin
  • Plasminogen
  • Peptide Hydrolases
  • Fibrinolysin